Innovation Stage
Expo Hall, #2519

Looking for something different? Check out ACC's Innovation Stage — a unique theater that provides and opportunity to enjoy a 30-minute focused discussion in a relaxed setting.

  Saturday, March 16
  Saturday, March 16

9:45 a.m. – 10:15 a.m.

PRALUENT (alirocumab) Injection: The Time to Treat is Now
Sponsored by Sanofi-Regeneron

Speakers:
Carl J. Lavie, MD, FACC, FACO, FCCP, FESPM; Medical Director, Cardiac Rehabilitation and Preventive Cardiology, John Ochsner Heart and Vascular Institute

10:45 a.m. – 11:15 a.m.

Advances in the Management of CAD/PAD: A New Treatment for Thrombotic Risk Reduction
Sponsored by Janssen Pharmaceuticals, Inc.

Patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) are at risk for major cardiovascular events, including cardiovascular death, myocardial infarction, and stroke. Join us for a presentation describing a newly approved approach to reducing the risk of these events.

Speaker:
Matthew C. Becker, MD

12:30 p.m. – 1:00 p.m.

Advances in the Management of CAD/PAD: A New Treatment for Thrombotic Risk Reduction
Sponsored by Janssen Pharmaceuticals, Inc.

Patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) are at risk for major cardiovascular events, including cardiovascular death, myocardial infarction, and stroke. Join us for a presentation describing a newly approved approach to reducing the risk of these events.

Speaker:
William J. French, MD

1:30 p.m. – 2:00 p.m.

Advances in the Management of CAD/PAD: A New Treatment for Thrombotic Risk Reduction
Sponsored by Janssen Pharmaceuticals, Inc.

Patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) are at risk for major cardiovascular events, including cardiovascular death, myocardial infarction, and stroke. Join us for a presentation describing a newly approved approach to reducing the risk of these events.

Speaker:
Marc Cohen, MD, FACC, FACP, FSCAI, FAHA

3:45 p.m. – 4:15 p.m.

Modern Afib Treatments for a Better Tomorrow
Sponsored by Biosense Webster, Inc.

Atrial fibrillation has become a virtual epidemic with over 3 million patients in the U.S. alone affected. For some of these patients, current pharmacological therapies are not effective.

We want to engage in a practical discussion about the diagnosis, progression, and treatment for atrial fibrillation by reviewing various patient cases. In addition to reviewing clinical information, we are going to discuss the patient management pathway for atrial fibrillation.

Please attend this seminar as the knowledge shared during this presentation will help us evaluate and discuss the continuum of treatment options with our atrial fibrillation patients.

Speaker: Saumil R. Oza, MD, FACC; Cardiac Electrophysiologist, Chief, Division of Cardiology St. Vincents-Riverside,Co-Director, The Atrial Fibrillation Institute, Jacksonville, Florida

  Sunday, March 17
  Sunday, March 17

9:45 a.m. – 10:15 a.m.

Patient Outcomes Matter: Contemporary Management of Heart Disease to Complete Revascularization
Sponsored by Boston Scientific

Join us for a look at the patient pathway to understand how to help your complex Coronary Artery Disease patients, including those with challenging lesions or those that have been previously told that nothing could be done, get back to a fuller life.

Speakers:
Emmanouil Brilakis, MD, PhD; Interventional Cardiologist, Minneapolis Heart Institute® at Abbott Northwestern Hospital, Researcher, Minneapolis Heart Institute Foundation, Minneapolis Heart Institute

Said Alsidawi, MD; Researcher, Minneapolis Heart Institute Foundation, Cardiologist, Minneapolis Heart Institute® at Abbott Northwestern Hospital and Ridgeview Medical Center, Minneapolis Heart Institute

12:30 p.m. – 1:00 p.m.

Heart Rate in Heart Failure: Hospitalization Risk and Health Related Quality of Life
Sponsored by Amgen

Join Dr Gregg C Fonarow for a disease state educational program that will focus on heart rate in heart failure and review the data suggesting elevated heart rate is a risk factor for hospitalization for Heart Failure and is associated with worse Health Related Quality of Life (HRQoL).

Speaker:
Dr. Gregg C. Fonarow

1:30 p.m. – 2:00 p.m.

I'm Afraid to Faint Again: Overview of Neurogenic Orthostatic Hypotension Diagnosis and Management
Sponsored by Lundbeck

This disease state education presentation provides an overview of orthostatic hypotension caused by dysautonomia — also known as neurogenic orthostatic hypotension (nOH). Learn more about the associated symptoms of nOH, as well as diagnostic and management considerations.

Speaker:
Sameh Mobarek, MD, FACC

3:45 p.m. – 4:15 p.m.

Patient Stands Up, Blood Pressure Goes Down: Diagnostic and Management Considerations for Symptomatic Neurogenic Orthostatic Hypotension
Sponsored by Lundbeck

A lively dual presentation between a Cardiologist and Neurologist on the identification and management of patients with orthostatic hypotension caused by dysautonomia—also known as neurogenic orthostatic hypotension (nOH). Presentation will include a brief overview of nOH and its symptoms, diagnostic and management considerations, and a Q&A with the audience.

Speakers:
Suzanne Feigofsky, MD

Stuart Isaacson, MD

  Monday, March 18
  Monday, March 18

9:45 a.m. – 10:15 a.m.

Kidney Care Protocols in the Cath Lab: Reduce the risk of AKI in high risk patients
Sponsored by Osprey Medical

Practical lessons and detailed protocols to protect high risk patients from kidney injury in the cath lab.

Speaker: Vishal Gupta, MD MPH FACC; Associate Clinical Professor MSU & WMED, Vice Chair, Ascension Borgess Heart Institute, Medical Director, Ascension Borgess Cardiovascular Lab, Associate Director, Interventional Fellowship Program, Co-Chair, Structural Heart Michigan Ascension, Ascension Borgess Medical Center, Kalamazoo, MI

12:30 p.m. – 1:00 p.m.

Hyperkalemia and RAASi Therapy: Walking the Fine Line
Sponsored by AstraZeneca Pharmaceuticals LP

The session will review clinical practice guidelines on renin-angiotensin-aldosterone system inhibition (RAASi) therapy; understand the relationship between RAASi therapy and hyperkalemia; review hyperkalemia-associated morbidity, mortality, and healthcare burden; and discuss goals for optimizing RAASi therapy in relation to elevated serum potassium levels.

Speaker:

Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP, FNKF, FCRSA; Vice Chair of Internal Medicine, Baylor University Medical Center


Schedule is current as of Feb. 1, 2019, and is subject to change. Please check back for updates.

*Innovation Stage presentations are not part of ACC.19, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

ADVERTISEMENT
ACC Logo
ACC.19 on Social Media:
      
2018 American College of Cardiology Foundation. Visit ACC.org
Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Cookie Policy Contact Us